ferric citrate has been researched along with Cardiovascular Diseases in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bino, A; Ganz, T; Salusky, IB | 1 |
| Ito, T; Iwashita, Y; Shigematsu, T | 1 |
| Vaziri, ND | 1 |
| Andrés, E; Ballarín, J; Barceló, P; Bover, J; Ortiz-Herbener, F | 1 |
4 review(s) available for ferric citrate and Cardiovascular Diseases
| Article | Year |
|---|---|
Mechanism of Action and Clinical Attributes of Auryxia
Topics: Administration, Intravenous; Anemia, Iron-Deficiency; Cardiovascular Diseases; Chelating Agents; Clinical Trials as Topic; Ferric Compounds; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Humans; Hyperphosphatemia; Iron; Iron Overload; Phosphates; Renal Insufficiency, Chronic; Risk Factors; Treatment Outcome | 2019 |
[Treatment for CKD-MBD(Chronic Kidney Disease-Mineral and Bone Disorder)].
Topics: Bone and Bones; Bone Diseases, Metabolic; Calcimimetic Agents; Calcinosis; Calcium Carbonate; Cardiovascular Diseases; Cinacalcet; Ferric Compounds; Fractures, Bone; Humans; Minerals; Parathyroidectomy; Phosphates; Phosphorus, Dietary; Renal Insufficiency, Chronic; Risk Factors; Sevelamer | 2016 |
Safety Issues in Iron Treatment in CKD.
Topics: Anemia, Iron-Deficiency; Cardiovascular Diseases; Cognitive Dysfunction; Diabetes Mellitus, Type 2; Disease Progression; Ferric Compounds; Hematinics; Humans; Iron Compounds; Iron Overload; Kidney Failure, Chronic; Oxidative Stress; Reactive Oxygen Species; Renal Dialysis; Renal Insufficiency, Chronic | 2016 |
[New therapy strategies in secondary hyperparathyroidism on dialysis (I): new concepts, new treatments].
Topics: Algorithms; Bile Acids and Salts; Calcium; Cardiovascular Diseases; Disease Progression; Drug Therapy, Combination; Epoxy Compounds; Female; Ferric Compounds; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Lanthanum; Male; Multivariate Analysis; Niacinamide; Phosphate-Binding Proteins; Phosphates; Phosphorus; Polyamines; Polyethylenes; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Renal Dialysis; Risk Factors; Sevelamer; Time Factors | 2005 |